US Senator Wyden Says He Will Keep Close Watch on Large Drugmakers and Insurers

The signal here is less about any specific enforcement threat than about where congressional attention is parked: drugmakers and insurers remain politically exposed targets, even without named companies or defined actions. For healthcare-facing RWA and tokenization projects, that matters because the underlying cash flows and counterparties sit squarely in these two sectors, and sustained scrutiny tends to slow deal-making and raise compliance expectations. The open question is whether this stays rhetorical pressure or turns into concrete legislative or oversight action, and which firms get named first.